<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076009</url>
  </required_header>
  <id_info>
    <org_study_id>CR103663</org_study_id>
    <secondary_id>54767414MMY3003</secondary_id>
    <secondary_id>2013-005525-23</secondary_id>
    <nct_id>NCT02076009</nct_id>
  </id_info>
  <brief_title>A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of daratumumab when combined with
      lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms
      of progression-free survival in participants with relapsed or refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (participants will be assigned by chance to study treatments),
      open-label (all participants and study personnel will know the identity of the study
      treatments), active-controlled (none of the study treatments are placebo), parallel-group
      (both treatment arms will run at the same time), multicenter study. In this study,
      daratumumab, lenalidomide, and low-dose dexamethasone (DRd) will be compared with
      lenalidomide and low dose dexamethasone (Rd) in participants with relapsed or refractory
      multiple myeloma. Participants will be randomized in a 1:1 ratio to receive either DRd or Rd.
      The study will include a Screening Phase, a Treatment Phase (involving treatment cycles of
      approximately 28 days in length), and a Follow-up Phase. The Treatment Phase will extend from
      the administration of the first dose of study medication until disease progression or
      unacceptable toxicity. Participants will also discontinue study treatment if: they become
      pregnant; have their dose held for more than 28 days (or if 3 consecutive planned doses of
      daratumumab are missed for reasons other than toxicity); or for safety reasons (for example,
      adverse event). The Follow-up Phase will begin at the end of treatment and will continue
      until death, loss to follow-up, consent withdrawal for study participation, or study end,
      whichever occurs first. Eligible participants from Rd group who have had sponsor-confirmed
      disease progression will be offered the option for treatment with daratumumab monotherapy (of
      28 days cycle). The primary endpoint will be progression-free survival (PFS). Analysis of the
      primary endpoint is anticipated to be performed at approximately 18 months after
      participant's first dose. Study end is anticipated at approximately 6 years after the last
      participant is randomized. Blood and urine samples will be obtained at time points during the
      study, together with bone marrow aspirates/biopsies and skeletal surveys. Participant safety
      will be assessed throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 23, 2014</start_date>
  <completion_date type="Anticipated">September 29, 2020</completion_date>
  <primary_completion_date type="Actual">March 7, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From randomization to either disease progression or death whichever occurs first until 3 years</time_frame>
    <description>PFS was defined as duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD was defined as meeting any one of following criteria: Increase of greater than equal to (&gt;=)25 percent (%) in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5 gram per deciliter (g/dL); Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be &gt;10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) that can be attributed solely to PC proliferative disorder.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression (TTP)</measure>
    <time_frame>From randomization to disease progression until 3 years</time_frame>
    <description>TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of &gt;=25% in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5 g/dL; Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be &gt;10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) that can be attributed solely to Plasma Cell (PC) proliferative disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better</measure>
    <time_frame>From randomization to disease progression (approximately up to 3 years)</time_frame>
    <description>VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or &gt;=90% reduction in serum M-protein plus urine M-protein &lt;100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of &gt;90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a &gt;=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and &lt;5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Negative Minimal Residual Disease (MRD)</measure>
    <time_frame>From randomization to the date of first documented evidence of PD until 3 years</time_frame>
    <description>Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10^- 4 threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>From randomization to disease progression (approximately up to 3 years)</time_frame>
    <description>Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: &gt;=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of &gt;=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a &gt;=50% reduction in the size of soft tissue plasmacytomas is also required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 5 years (anticipated) after the last participant is randomized</time_frame>
    <description>Overall survival was measured from the date of randomization to the date of the participant's death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>From randomization up to first documented CR or PR until 3 years</time_frame>
    <description>Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From randomization to the date of first documented evidence of PD until 3 years</time_frame>
    <description>DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of &gt;=25% in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5g/dL; Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be &gt;10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5mg/dL) that can be attributed solely to PC proliferative disorder.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">569</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Daratumumab + lenalidomide + dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide + dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During each 28-day treatment cycle, participants will receive daratumumab alone in daratumumab monotherapy group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards.</description>
    <arm_group_label>Daratumumab + lenalidomide + dexamethasone</arm_group_label>
    <arm_group_label>Daratumumab monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.</description>
    <arm_group_label>Daratumumab + lenalidomide + dexamethasone</arm_group_label>
    <arm_group_label>Lenalidomide + dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 18.5).</description>
    <arm_group_label>Daratumumab + lenalidomide + dexamethasone</arm_group_label>
    <arm_group_label>Lenalidomide + dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have documented multiple myeloma and measurable disease

          -  Must have received at least 1 prior line of therapy for multiple myeloma and achieved
             a response (partial response or better) to at least one prior regimen

          -  Must have documented evidence of progressive disease as defined by the International
             Myeloma Working Group criteria on or after their last regimen

          -  Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2

          -  If a participant has received subsequent anticancer therapy (salvage therapy), the
             participant must have a &quot;wash-out period&quot; defined as 2 weeks or 5 pharmacokinetic
             half-lives of the treatment, whichever is longer, before the planned start date of
             daratumumab monotherapy. The only exception is the emergency use of a short course of
             corticosteroids (equivalent of dexamethasone 40 milligram per day for a maximum of 4
             days) before Daratumumab monotherapy

        Exclusion Criteria:

          -  Has received any of the following therapies: daratumumab or other anti-CD38 therapies

          -  Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of
             the treatment

          -  Disease shows evidence of refractoriness or intolerance to lenalidomide or if
             previously treated with a lenalidomide-containing regimen the participant is excluded
             if he or she discontinued due to any adverse event related to prior lenalidomide
             treatment

          -  Has received autologous stem cell transplantation within 12 weeks before the date of
             randomization, or previously received an allogenic stem cell transplant (regardless of
             timing), or planning to undergo a stem cell transplant prior to progression of disease

          -  History of malignancy (other than multiple myeloma) within 5 years before the first
             dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of
             the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion,
             that in the opinion of the investigator, with concurrence with the sponsor's medical
             monitor, is considered cured with minimal risk of recurrence within 5 years)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geelong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southport</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey N/A</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto N/A</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens Attica</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hitachi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Narita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohgaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibukawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tachikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brzozow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorzów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Legnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slupsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dzerzhinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Laguna (Santa Cruz De Tenerife)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>December 20, 2016</results_first_submitted>
  <results_first_submitted_qc>December 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2017</results_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
          <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
        </group>
        <group group_id="P2">
          <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
          <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="249"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
          <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
        </group>
        <group group_id="B2">
          <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
          <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="283"/>
            <count group_id="B2" value="286"/>
            <count group_id="B3" value="569"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="8.84"/>
                    <measurement group_id="B2" value="64.4" spread="9.03"/>
                    <measurement group_id="B3" value="64.4" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Disease (ISS)</title>
          <description>The International Staging System (ISS) consists of following 3 stages - Stage I: serum beta2-microglobulin less than (&lt;)3.5 milligram per liter (mg/l) and albumin greater than or equal to (&gt;=) 3.5 gram per 100 Milliliter (g/100 ml); Stage II: neither stage I nor stage III and Stage III: serum beta2-microglobulin &gt;= 5.5 mg/l.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of Prior Lines of Therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD was defined as meeting any one of following criteria: Increase of greater than equal to (&gt;=)25 percent (%) in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5 gram per deciliter (g/dL); Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be &gt;10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) that can be attributed solely to PC proliferative disorder.</description>
        <time_frame>From randomization to either disease progression or death whichever occurs first until 3 years</time_frame>
        <population>Intent-to-treat (ITT) analysis set included all participants who were randomly assigned to the daratumumab, lenalidomide, dexamethasone (DRd) or lenalidomide, low-dose dexamethasone (Rd) group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD was defined as meeting any one of following criteria: Increase of greater than equal to (&gt;=)25 percent (%) in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5 gram per deciliter (g/dL); Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be &gt;10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) that can be attributed solely to PC proliferative disorder.</description>
          <population>Intent-to-treat (ITT) analysis set included all participants who were randomly assigned to the daratumumab, lenalidomide, dexamethasone (DRd) or lenalidomide, low-dose dexamethasone (Rd) group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.43" lower_limit="13.86">Upper limit of 95% confidence interval (CI) was not estimable due to short follow-up by participants.</measurement>
                    <measurement group_id="O2" value="NA">Median and 95% CI was not estimable due to short follow-up by participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression (TTP)</title>
        <description>TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of &gt;=25% in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5 g/dL; Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be &gt;10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) that can be attributed solely to Plasma Cell (PC) proliferative disorder.</description>
        <time_frame>From randomization to disease progression until 3 years</time_frame>
        <population>ITT analysis set included all participants who were randomly assigned to the DRd or Rd group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression (TTP)</title>
          <description>TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of &gt;=25% in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5 g/dL; Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be &gt;10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) that can be attributed solely to Plasma Cell (PC) proliferative disorder.</description>
          <population>ITT analysis set included all participants who were randomly assigned to the DRd or Rd group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.43" lower_limit="14.78">Upper limit of 95% CI was not estimable due to short follow-up.</measurement>
                    <measurement group_id="O2" value="NA">Median and 95% CI was not estimable due to short follow-up.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better</title>
        <description>VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or &gt;=90% reduction in serum M-protein plus urine M-protein &lt;100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of &gt;90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a &gt;=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and &lt;5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.</description>
        <time_frame>From randomization to disease progression (approximately up to 3 years)</time_frame>
        <population>Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better</title>
          <description>VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or &gt;=90% reduction in serum M-protein plus urine M-protein &lt;100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of &gt;90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a &gt;=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and &lt;5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.</description>
          <population>Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" lower_limit="38.3" upper_limit="50.3"/>
                    <measurement group_id="O2" value="75.8" lower_limit="70.4" upper_limit="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Negative Minimal Residual Disease (MRD)</title>
        <description>Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10^- 4 threshold.</description>
        <time_frame>From randomization to the date of first documented evidence of PD until 3 years</time_frame>
        <population>ITT analysis set included all participants who were randomly assigned to the DRd or Rd group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Negative Minimal Residual Disease (MRD)</title>
          <description>Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10^- 4 threshold.</description>
          <population>ITT analysis set included all participants who were randomly assigned to the DRd or Rd group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: &gt;=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of &gt;=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a &gt;=50% reduction in the size of soft tissue plasmacytomas is also required.</description>
        <time_frame>From randomization to disease progression (approximately up to 3 years)</time_frame>
        <population>Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: &gt;=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of &gt;=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a &gt;=50% reduction in the size of soft tissue plasmacytomas is also required.</description>
          <population>Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4"/>
                    <measurement group_id="O2" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival was measured from the date of randomization to the date of the participant's death.</description>
        <time_frame>Up to approximately 5 years (anticipated) after the last participant is randomized</time_frame>
        <population>ITT analysis set included all participants who were randomly assigned to the DRd or Rd group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival was measured from the date of randomization to the date of the participant's death.</description>
          <population>ITT analysis set included all participants who were randomly assigned to the DRd or Rd group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not calculated and reported due to short follow-up by participants.</measurement>
                    <measurement group_id="O2" value="NA">Data was not calculated and reported due to short follow-up by participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better.</description>
        <time_frame>From randomization up to first documented CR or PR until 3 years</time_frame>
        <population>Response-evaluable set is defined as participants who have a confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening visit. In addition, participants must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better.</description>
          <population>Response-evaluable set is defined as participants who have a confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening visit. In addition, participants must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.1" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of &gt;=25% in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5g/dL; Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be &gt;10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5mg/dL) that can be attributed solely to PC proliferative disorder.</description>
        <time_frame>From randomization to the date of first documented evidence of PD until 3 years</time_frame>
        <population>Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment. Here 'N' signifies number of participants who had PR or better response.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
            <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
          </group>
          <group group_id="O2">
            <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
            <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of &gt;=25% in level of serum M-protein from lowest response value and absolute increase must be &gt;=0.5g/dL; Increase of &gt;=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be &gt;=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of &gt;=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be &gt;10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium &gt;11.5mg/dL) that can be attributed solely to PC proliferative disorder.</description>
          <population>Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment. Here 'N' signifies number of participants who had PR or better response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="17.4">Upper limit of 95% CI was not estimable due to high censoring rate and lesser number of responders who progressed.</measurement>
                    <measurement group_id="O2" value="NA">Median and 95% CI was not estimable due to high censoring rate and lesser number of responders who progressed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Population included participants who were randomized and received at least 1 dose of any study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide, Low-dose Dexamethasone (Rd)</title>
          <description>Participants received lenalidomide at a dose of 25 milligram (mg) orally on Days 1 through 21 of each treatment cycle and dexamethasone as a total dose of 40 mg weekly (or 20 mg weekly for participants greater than (&gt;) 75 years old or with a body mass index less than [&lt;] 8.5).</description>
        </group>
        <group group_id="E2">
          <title>Daratumumab, Lenalidomide, Dexamethasone (DRd)</title>
          <description>Participants received daratumumab 16 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks); once only (on Day 1) during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each treatment cycle and dexamethasone was administered as a total dose of 40 mg weekly (or 20 mg weekly for participants &gt; 75 years old or with a body mass index &lt; 8.5).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hyperviscosity Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Sideroblastic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Thrombotic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cardiac Amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Sinus Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Posterior Capsule Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Diverticular Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Angiodysplasia Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Systemic Inflammatory Response Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bronchitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Candida Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Enterocolitis Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Escherichia Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Extradural Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>H1n1 Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Haemophilus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Infective Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Keratitis Fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Listeria Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Nasal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Necrotising Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Oral Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Parainfluenzae Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia Haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia Influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia Klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia Legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Salmonella Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Uterine Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Varicella Zoster Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Peroneal Nerve Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Diagnostic Procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Troponin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of Jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Spinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Monocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Benign Anorectal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bowen's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Epstein-Barr Virus Associated Lymphoproliferative Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Plasma Cell Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Rectal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Carotid Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Cognitive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Intercostal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Nervous System Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Trigeminal Nerve Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Viith Nerve Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Depressive Symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Urethral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pulmonary Calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Venous Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="274" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="276" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="283"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="283"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Janssen R&amp;D US</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

